In prespecified pooled analyses, the percentage of patients with disability progression confirmed at 12 weeks was significantly lower with ocrelizumab than with interferon beta-1a (9.1% vs.
#OPERA BETA 46 AN ERROR HAS OCCURRED TRIAL#
0.29 46% lower rate with ocrelizumab P<0.001) and in trial 2 (0.16 vs. The annualized relapse rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0.16 vs. The primary end point was the annualized relapse rate. In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. The most trusted, influential source of new medical knowledge and clinical best practices in the world.ī cells influence the pathogenesis of multiple sclerosis. Information and tools for librarians about site license offerings. Valuable tools for building a rewarding career in health care. The authorized source of trusted medical research and education for the Chinese-language medical community. The most advanced way to teach, practice, and assess clinical reasoning skills. Information, resources, and support needed to approach rotations - and life as a resident. The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams.
NEW! Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Ĭoncise summaries and expert physician commentary that busy clinicians need to enhance patient care.
NEW! A digital journal for innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
0 kommentar(er)
